Boston Scientific (BSX) Financials: History & Chart

Boston Scientific Corporation (BSX)BSXBoston Scientific Corporation

About Boston Scientific Corporation

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

Marlborough, MA

59,000 employees

www.bostonscientific.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Michael F. Mahoney

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	21.00B	5.44B	5.20B	5.29B	5.07B	5.06B	4.66B	4.56B	4.21B
Cost of Goods Sold	6.05B	1.59B	1.59B	1.35B	1.52B	1.64B	1.71B	1.89B	1.56B
Gross Profit	14.94B	3.85B	3.61B	3.94B	3.54B	3.42B	2.95B	2.67B	2.65B
Gross Profit Margin	71.2%	70.7%	69.4%	74.5%	69.9%	67.7%	63.3%	58.6%	62.9%
Total Operating Expenses	10.12B	2.35B	2.54B	2.73B	2.49B	2.60B	2.05B	2.08B	1.97B
Research & Development	2.15B	553.00M	516.00M	569.00M	514.00M	526.00M	443.00M	460.00M	407.00M
Selling, General & Administrative	7.16B	1.80B	1.78B	1.83B	1.74B	1.72B	1.60B	1.61B	1.56B
Operating Income (EBIT)	4.54B	1.21B	1.07B	1.21B	1.05B	819.00M	896.00M	589.00M	674.00M
Operating Margin	21.6%	22.2%	20.6%	22.8%	20.7%	16.2%	19.2%	12.9%	16.0%
Income Before Tax (EBT)	3.86B	1.06B	1.16B	700.00M	939.00M	941.00M	805.00M	585.00M	668.00M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	22.00M	N/A
Interest Expense	-9.00M	-276.00M	90.00M	90.00M	87.00M	90.00M	87.00M	139.00M	83.00M
Other Income/Expense	-674.00M	-147.00M	90.00M	-506.00M	-111.00M	122.00M	-91.00M	-4.00M	-6.00M
Net Income	3.67B	910.00M	1.34B	668.00M	755.00M	793.00M	674.00M	566.00M	469.00M
Income Tax Expense	193.00M	155.00M	-176.00M	31.00M	183.00M	146.00M	133.00M	23.00M	200.00M
Net Profit Margin	17.5%	16.7%	25.7%	12.6%	14.9%	15.7%	14.5%	12.4%	11.1%
EBITDA	5.24B	856.00M	1.42B	1.57B	1.39B	1.16B	1.22B	937.00M	981.00M
EBITDA Margin	25.0%	15.7%	27.3%	29.7%	27.5%	22.8%	26.2%	20.5%	23.3%
Depreciation & Amortization	707.00M	-351.00M	351.00M	365.00M	342.00M	336.00M	325.00M	348.00M	307.00M
EPS Basic	2.48	0.62	0.90	0.45	0.51	0.54	0.46	0.38	0.32
EPS Diluted	2.46	0.61	0.90	0.45	0.50	0.53	0.45	0.38	0.32
Shares Outstanding	1.48B	1.48B	1.48B	1.48B	1.48B	1.48B	1.48B	1.47B	1.47B
Diluted Shares Outstanding	1.48B	1.48B	1.50B	1.50B	1.50B	1.49B	1.49B	1.49B	1.49B

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	20.07B	16.75B	14.24B	12.68B	11.89B	9.91B	10.73B	9.82B
Cost of Goods Sold	6.22B	6.48B	5.41B	4.97B	4.43B	4.34B	3.86B	3.35B
Gross Profit	13.85B	10.27B	8.83B	7.71B	7.46B	5.58B	6.88B	6.48B
Gross Profit Margin	69.0%	61.3%	62.0%	60.8%	62.8%	56.2%	64.1%	65.9%
Total Operating Expenses	9.88B	7.63B	6.65B	5.89B	5.54B	4.97B	5.17B	4.74B
Research & Development	2.05B	1.61B	1.41B	1.32B	1.20B	1.14B	1.17B	1.11B
Selling, General & Administrative	6.89B	5.98B	5.19B	4.52B	4.29B	3.79B	3.93B	3.56B
Operating Income (EBIT)	3.97B	2.63B	2.18B	1.82B	1.92B	601.00M	1.71B	1.74B
Operating Margin	19.8%	15.7%	15.3%	14.4%	16.2%	6.1%	15.9%	17.7%
Income Before Tax (EBT)	3.38B	2.28B	1.99B	1.14B	1.08B	-79.00M	687.00M	1.42B
Interest Income	N/A	107.00M	22.00M	10.00M	4.00M	3.00M	30.00M	3.00M
Interest Expense	349.00M	387.00M	272.00M	464.00M	349.00M	468.00M	513.00M	269.00M
Other Income/Expense	-586.00M	-353.00M	-196.00M	-683.00M	-846.00M	-680.00M	-1.02B	-315.00M
Net Income	2.89B	1.85B	1.59B	698.00M	1.04B	-82.00M	4.70B	1.67B
Income Tax Expense	493.00M	436.00M	393.00M	443.00M	36.00M	2.00M	-4.01B	-249.00M
Net Profit Margin	14.4%	11.1%	11.2%	5.5%	8.7%	-0.8%	43.8%	17.0%
EBITDA	5.34B	3.90B	3.38B	2.96B	3.02B	1.72B	2.72B	2.63B
EBITDA Margin	26.6%	23.3%	23.7%	23.3%	25.4%	17.4%	25.4%	26.8%
Depreciation & Amortization	1.37B	1.27B	1.20B	1.14B	1.09B	1.12B	1.01B	894.00M
EPS Basic	1.96	1.26	1.08	0.45	0.69	-0.08	3.38	1.21
EPS Diluted	1.94	1.25	1.07	0.45	0.69	-0.08	3.33	1.19
Shares Outstanding	1.48B	1.47B	1.45B	1.43B	1.42B	1.42B	1.39B	1.38B
Diluted Shares Outstanding	1.49B	1.49B	1.46B	1.44B	1.43B	1.42B	1.41B	1.40B

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.